IPO & Public Markets

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

With wins from the Cerebras and SpaceX IPOs, Open Doors Partners hires Ravi Chiruvolu to deepen its expertise in a pivotal moment for private markets.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

RECONOVA's massively oversubscribed IPO met a cool reception on its first day, signaling a new era where AI firms must prove profitability, not just potential.

A new $105M SPAC enters the fray. We examine its veteran leadership, its cross-sector strategy, and what it takes to win in today's SPAC market.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

Gaming giant Flutter Entertainment has abandoned the London Stock Exchange for New York. It's more than a listing change; it's a strategic realignment.

The sandwich giant's IPO isn't just about cashing in. It's a strategic move to fund global expansion and dominate a fiercely competitive fast-casual market.

Catalyst Acquisition Corp. has closed its $200M IPO. Led by media veterans, the SPAC is now on the hunt for a major deal in the booming gaming and media sectors.

A new $75 million SPAC has hit the market, but this isn't just another Wall Street vehicle. It's a high-stakes search for the next technology titan.

As Lyntris files for its IPO under the ticker 'LYNX', it's more than a public offering; it's a test of market appetite for the future of connected warfare.

Athena Capital bolsters its 'private-to-exit' platform with key hires, adding academic rigor and operational prowess to guide tech firms through the final mile to liquidity.

B&R Technology Merger Corp. just raised $325M. With a veteran tech team at the helm, their IPO isn't just another blank check—it's a calculated bet.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

With a historic $26.5B NASDAQ listing, SK hynix solidifies its crucial role in the AI supply chain, escalating the high-stakes race for memory dominance.

Sivers Semiconductors pushed its earnings dates. This isn't a sign of trouble; it's the steep cost of admission to Wall Street's premier league.

After a blockbuster NYSE debut, a deep dive into how manufacturer Doncasters will use $1B to pay down debt and dominate the high-tech components market.

As Cartesian Growth Corp IV launches its IPO, it's not just another blank check. It’s a test case for a new, disciplined era of strategic acquisitions.

Fresh off its IPO, EagleRock Land wipes its debt slate clean. How this strategic reset positions the company to dominate the future of energy and infrastructure.